{
    "clinical_study": {
        "@rank": "53737", 
        "arm_group": {
            "arm_group_label": "Indocyanine Green", 
            "arm_group_type": "Experimental", 
            "description": "Intravenous injection of 0,25 mg/kg Indocyanine Green"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if NIR fluorescent imaging is an effective\n      approach to detect the margins of head and neck tumours or lymph nodes draining the tumour"
        }, 
        "brief_title": "NIR Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After iv Injection of ICG", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": "Head and Neck Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Primary objective:\n\n      definition of the distribution of intravenously injected ICG in the normal and pathological\n      lymph nodes draining the dissected tumor in head and neck cancer patients or in nodes\n      recurrences in head and neck cancer\n\n      Secondary objectives:\n\n        -  Evaluation of the ability of NIR fluorescence imaging to determine the tumoral volume,\n           specifically the margins of the tumoral tissues (in the operating room and in the\n           pathology department)\n\n        -  Analysis of the correlation between ICG fluorescence and tumoral invasion in the\n           dissected lymph nodes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients requiring neck dissection with or without resection of the primary (the\n             decision and the type of neck dissection are preliminary decided during head and neck\n             multidisciplinary oncologic consultation).\n\n          -  Informed consent form signed.\n\n        Exclusion Criteria:\n\n          -  Age less than18 years old.\n\n          -  Inability to give informed consent.\n\n          -  History of allergy or hypersensitivity against the investigational product (its\n             active substance or ingredients), to iodine or to shellfish.\n\n          -  Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or\n             disseminated autonomies of the thyroid gland.\n\n          -  Documented coronary disease.\n\n          -  Advanced renal impairment (creatinine > 1,5mg/dl).\n\n          -  During the 2 weeks before the enrolment, concurrent medication which reduces or\n             increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).\n\n          -  Pregnancy, breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027831", 
            "org_study_id": "HN-ICG-IV"
        }, 
        "intervention": {
            "arm_group_label": "Indocyanine Green", 
            "intervention_name": "Indocyanine Green", 
            "intervention_type": "Drug", 
            "other_name": "ICG"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "lymph nodes", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "antoine.digonnet@bordet.be", 
                "last_name": "Antoine Digonnet, MD", 
                "phone": "003225413319"
            }, 
            "contact_backup": {
                "email": "pierre.bourgeois@bordet.be", 
                "last_name": "Pierre Bourgeois, MD", 
                "phone": "003225413276"
            }, 
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1000"
                }, 
                "name": "Jules Bordet Institute"
            }, 
            "investigator": {
                "last_name": "Antoine Digonnet, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Near-infrared Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After Intravenous Injection of Indocyanine Green (a Feasibility Study)", 
        "overall_official": {
            "affiliation": "Jules Bordet Institute", 
            "last_name": "Antoine Digonnet, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After IV injection of Indocyanine Green just before the surgery to head and neck cancer patients, we will study the fluorescence due to ICG in cervical lymph nodes and in the primary lesion.", 
            "measure": "Evaluation of the capacity of ICG to detect cervical lymph nodes after IV injection", 
            "safety_issue": "No", 
            "time_frame": "7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jules Bordet Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jules Bordet Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}